Oral Anticoagulation

Cardiology Secrets: Fourth Edition

Volumn , Issue , 2013, Pages 380-392

  Spinler, Sarah A ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902053198     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4815-0.00053-2     Document Type: Chapter

References (22)

1. Agency for Healthcare Research and Quality: Blood thinner pills: your guide to using them safely Available at, Accessed Sep 10, 2012. http://www.ahrq.gov/consumer/btpills.htm.
2. Bonow R.O., Carabello B.A., Chatterjee K., et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008, 118:e523-e661.
3. Dewilde W.J.M., Oirbans T., Verheugt F.W.A., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised controlled trial, Lancet published online February 13, 2013. Available at, Accessed March 4, 2013. http://dx.doi.org/10.1016/S0140-6736(12http%3A//dx.doi.org/10.1016/S0140-6736(12)62177-1.
4. Douketis J.D., Spyropoulos A.C., Spencer F.A., et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, ed 9: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl 2):e326S-e350S. Erratum in: Chest 2012 141 1129.
5. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
6. Eliquis (apixaban) prescribing information December 2012, Bristol-Myers Squibb Company, Princeton, NJ.
7. European Medicines Agency: Questions and answers on the review of bleeding risk with Pradaxa (dabigatran etexilate) Available at, Accessed Sep 10, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/05/WC500127768.pdf.
8. Faxon D.P., Eikelboom J.W., Berger P.B., et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interven 2011, 4:522-534.
9. Furie K.L., Goldstein L.B., Albers G.W., et al. Oral antithrombotic agents for prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012, 43:3442-3453.
10. Guyatt G.H., Akl E.A., Crowther M., et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, ed 9: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl 2):7S-47S.
11. Kaatz M., Kouides P.A., Garcia D.A. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012, 87:S141-S145.
12. Kearon C., Akl A.L., Comorota A.J., et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, ed 9: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl 2):e419S-e494S.
13. Lansberg M.G., O'Donnell M.J., Khatri P., et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, ed 9: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl 2):e601-e636S.
14. Lindenfeld J., Albert N.M., Boehmer J.P., et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010, 16:e1-e194.
15. Marlu R., Enkelejda H., Paris A., et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost 2012, 108:217-224.
16. O'Gara P.T., Kushner F.G., Ascheim D.D., et al. 2013 ACCF/AHA Guideline for the Management of ST-elevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012, 61:e78-140.
17. Pradaxa (dabigatran etexilate) prescribing information 2012, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.
18. Samama M.M., Contact G., Spiro T.E., et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemostas 2012, 107:379-387.
19. U.S. Food and Drug Administration: Drug development and drug interactions: table of substrates, inhibitors and inducers Available at, Accessed Sep 10, 2012. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm%20.
20. Whitlock R.P., Sun J.C., Fremes S.E., et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, ed 9: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl 2):e576S-e600S.
21. You J.J., Singer D.E., Lane D.A., et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, ed 9: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl 2):e531S-e575S.
22. Xarelto (rivaroxaban) prescribing information March, 2013, Janssen Pharmaceuticals, Inc, Titusville, NJ.